They have found this drug to be largely effective in the prevention and treatment of infections. According to the team, the small size of the biologic not only increases its potential for diffusion into tissues to better neutralise the virus, but also enables administration by alternative routes, including inhalation.
Ab8 also does not bind to human cells, which is a sign that it won't cause negative side effects in patients.
Can Be A Preventive Measure As Well?
During testing of Ab8 to a live SARS-CoV-2 virus at the University of Texas Medical Branch Center for Biodefense and Emerging Diseases, they found that it blocked the virus from entering cells.
He added that larger antibodies have been effective against other infectious diseases, giving the world a hope that they could also cure and prevent COVID-19 infections. Xianglei Liu of Pitt is also co-lead author.
What Do The Researchers Say About The Discovery Of The Antibody?
How does it do it? The tiny antibody component is the variable in the heavy chain (VH) of an immunoglobulin.
The cocktail of drugs targets two components in the spike protein of the Covid-19 virus with the aim of interrupting its ability to infect.
Researchers are also "thinking outside the box" for how the drug could be administered, stating it may be able to be inhaled or through a superficial injection, instead of an IV.
A tiny part of an antibody that is highly effective in preventing and treating coronavirus in animal models was discovered by University of Pittsburgh scientists and could serve as a potential therapeutic against COVID-19.
"The idea is that the antibody will block the spread of the virus throughout the body".
Dimiter Dimitrov, director of the University of Pittsburgh's Center for Antibody Therapeutics, started working with assistant director Wei Li and other scientists this spring to identify an antibody that neutralizes the SARS-CoV-2 virus. There are good reasons to be excited about this new development - RECOVERY will provide a robust assessment of the effect of this lab-manufactured monoclonal antibody combination treatment in hospitalized patients. This medicine can be used against SARS-Cov-2. The rodents that were treated with the drug had significantly less (10-fold less of the amount) of infectious virus compared to those that were not treated.
Researchers at the University of British Columbia uncovered the unique way Ab8 neutralizes the virus so effectively by using sophisticated electron microscopic techniques.
"The COVID-19 pandemic is a global challenge facing humanity", said Mellors, "but biomedical science and human ingenuity are likely to overcome it". "We hope that the antibodies we have discovered will contribute to that triumph".